Australia's Tetratherix rises after FDA review update on Tegenix application

Tetratherix

06/10/2026 24:15

** Shares of Tetratherix TTX.AX rise as much as 5% to A$6.70, their highest level since September 23
** Medical technology company says US FDA has completed an initial review of its application for Tegenix
** Tegenix is a product used with bone graft materials in dental and oral procedures
** Says FDA confirmed key parts of the filing, including device classification, chosen comparison device and performance data
** Adds it is preparing a response and views update as validation of the Tegenix submission and its Tetramatrix platform
** Stock up 104.3% this year, including the day's move

 (Reporting by Roshan Thomas in Bengaluru)
 ((Roshan.Thomas@thomsonreuters.com))